Many studies have shown that light therapy works for seasonal affective disorder, but does it work for non-seasonal major depression? That’s less clear. Systematic reviews have yielded inconclusive results, in part because prior studies have had methodological weaknesses. A new study with a robust design was just published.
Read More
Dr. Bodkin discusses methods for approaching treatment resistant depression and his perspective on depressive illness as a final common pathway for a number of different brain problems.
Read More
Since 2011, 3 new antidepressants have been approved by the FDA, and another (ketamine) has been generating buzz as a potential off-label medication for depression. In this article, we’ll take a step back and review the data on vilazodone (Viibryd), levomilnacipran (Fetzima), vortioxetine (Brintellix), and ketamine.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.